Clinical Trial Update: Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating motesanib in combination with paclitaxel and carboplatin for advanced non-squamous non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• motesanib (motesanib)

Snippet

Sponsor: Takeda | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: TERMINATED